GlassScriptPhysician profile
Iman Boston
NPI 1750744173
$59,423.57
in general payments reported to CMS, 2019-2025
15 companies · $3,579 in 2025
The $3,579 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $32.95 · 2021: $345 · 2022: $99.15 · 2023: $28K · 2024: $27K · 2025: $3,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $50K · Consulting Fee: $3,065 · Travel and Lodging: $2,954 · Food and Beverage: $2,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $50,000.00 |
| Consulting Fee | $3,065.00 |
| Travel and Lodging | $2,953.71 |
| Food and Beverage | $2,656.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $54,475.88 | 2021-2025 | Resolution 360 Clip, Axios, Exalt Model D |
| Olympus Medical Systems Corporation | $2,065.00 | 2025 | Gastrointestinal Videoscope |
| Gyrus Acmi, INC. | $1,000.00 | 2025 | |
| Wilson Cook Medical Incorporated | $768.85 | 2023 | Fusion |
| Abbvie INC. | $280.99 | 2021-2023 | |
| Cook Medical LLC | $173.23 | 2023 | Hemospray |
| Steris Corporation | $121.63 | 2021 | |
| Pfizer INC. | $110.41 | 2019 | |
| Amgen INC. | $108.38 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.15 | 2022 | |
| Lilly USA, LLC | $76.52 | 2023 | |
| Exact Sciences Corporation | $57.85 | 2024 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $32.95 | 2020 | |
| Arbor Pharmaceuticals, INC. | $28.57 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iman Boston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.